参考资料：
[1]Herman， M.A.， Metabolic liver disease — what’s in a name？ Nature Reviews Endocrinology， 2026.
[2]Jelena Todoric et al. (2020) Fructose stimulated de novo lipogenesis is promoted by inflammation. Nature Metabolism
[3]Giovanni Targher， et al.， (2025). Non-alcoholic fatty liver disease： a multisystem disease requiring a multidisciplinary and holistic approach. The Lancet Gastroenterology & Hepatology
[4]非酒精性脂肪性肝病防治指南(2018更新版)[J].传染病信息，2018，31(05)：393-402+420.
[5]Parthasarathy， G. et al. “Pathogenesis of Nonalcoholic Steatohepatitis： An Overview.” Hepatology Communications 4 (2020)： 478 - 492.
[6]Younossi， Z. et al. “Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates.” Clinical Gastroenterology & Hepatology 17 (2019)： 748–755.e3.
[7]Younossi， Z. et al. “Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.” Hepatology 69 (2019)： n. pag.
[8]Younossi， Z. et al. “Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis： Implications for Liver Transplantation.” Transplantation (2019)： n. pag.
[9]Harrison， S. et al. “NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis.” Hepatology (Baltimore， Md.) 71 (2019)： 1198 - 1212.
[10]Choi， Hannah S. J. et al. “Nonalcoholic Steatohepatitis Is Associated With Liver‐Related Outcomes and All‐Cause Mortality in Chronic Hepatitis B.” Hepatology 71 (2019)： n. pag.
[11]Diehl， A. and Christopher Day. “Cause， Pathogenesis， and Treatment of Nonalcoholic Steatohepatitis.” The New England Journal of Medicine 377 (2017)： 2063–2072.
[12]Kim， D. et al. “Predictors of nonalcoholic steatohepatitis and significant fibrosis in non‐obese nonalcoholic fatty liver disease.” Liver International 39 (2019)： 332 - 341.
[13]Younossi， Z. et al. “Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.” Hepatology 68 (2018)： n. pag.
